introduction
In postmenopausal women, the third-generation nonsteroidal aromatase inhibitors (NSAIs) are now widely used as adjuvant therapy, as well as in the first-line setting for hormonesensitive advanced breast cancer. Eventually, disease progresses and development of novel treatment strategies are highly expected. It is common clinical practice to use different hormonal agents in sequence for those patients who remain endocrine responsive, owing to their favorable toxicity profile and a high disease control rate. The estrogen receptor (ER) antagonist fulvestrant and the steroidal aromatase inhibitor (AI) exemestane demonstrated similar efficacy as second-line therapy [1, 2] . Recently, the combination of exemestane with the PI3K/ mTOR inhibitor everolimus showed remarkable results in this clinical setting [3] .
The recent revival of 'old-fashioned' additive treatments, such as estradiol, suggests a critical role for the re-evaluation of the optimal sequencing of hormonal therapy in advanced breast cancer [4, 5] . Novel agents carry substantial price tags and are mostly cost-prohibitive in low-and middle-income countries, reinforcing the need to explore such alternatives [6] .
Megestrol acetate (MA) is a semi-synthetic progestin that has a longstanding history in the treatment of breast cancer. The mechanism of action of MA is not yet fully understood. It has physiologic effects similar to natural progesterone and its antitumoral activity may involve interaction with the steroid receptors, such as progesterone, glucocorticoid and androgen receptors. Other mechanisms of action have been proposed including reduced cellular estrogen uptake and growth factor interactions as well as suppression of adrenal steroid production and ovarian secretion of androgens in postmenopausal women [4, 7] .
A small prospective randomized trial compared MA with aminoglutethimide (AG) as the second-line treatment in metastatic breast cancer and showed similar efficacy between the agents [8] . MA has been used less often in the management of breast cancer since the advent of AIs and fulvestrant. There is previous evidence demonstrating responses to MA after disease progression on AG or tamoxifen: partial response (PR) and stable disease were 4% and 48%, respectively, with a median duration of clinical benefit of 8 months [9] . Recent retrospective data from our group showed a median time-to-treatment failure of 16 weeks with MA after NSAI progression in patients with endocrine-responsive advanced breast cancer [10] .
This phase II trial evaluated the efficacy and toxicity profile of MA in postmenopausal women with hormone-sensitive advanced breast cancer who had experienced disease progression on a third-generation NSAI. methods study design and patient eligibility A two-stage, single-institution, phase II clinical trial was conducted among postmenopausal women whose breast cancer had progressed during treatment with a NSAI. Hormone sensitivity was defined as either a lack of disease progression during at least 12 months of adjuvant NSAI therapy, or a minimum of 6 months of NSAI treatment duration for advanced disease. Chemotherapy was allowed for metastatic disease, but the AI had to be the most recent treatment before enrollment. Bisphosphonate therapy was permitted if initiated before study entry. Patients could have measurable or evaluable disease and had to have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤2. Adequate hematological, renal, and hepatic function was required. Exclusion criteria included a history of extensive liver and/or lung involvement, brain-leptomeningeal metastases, deep vein thrombosis (DVT) or pulmonary embolism, uncontrolled hypertension, stroke, congestive heart failure, or acute myocardial infarction.
study treatment and assessments
Patients received MA at a single oral dose of 160 mg daily. After initiation of therapy, a physician saw patients and reviewed complete blood counts and biochemistry every 4 weeks during the first 16 weeks, and every 8 weeks thereafter. Imaging studies were carried out on weeks 8 and 16, and every 12-16 weeks thereafter. Bone scans were repeated for patients with documented bone disease at week 8 and then every 12 weeks. Doppler ultrasound of the lower extremities was carried out every 8 weeks throughout the whole study period. Treatment was continued until evidence of disease progression, unacceptable toxicity, or withdrawal of consent. Subsequent lines of therapy were at the physician's discretion.
The primary end point of this study was clinical benefit rate (CBR) defined as complete response, PR, or stable disease (SD) for >24 weeks, according to the RECIST 1.0 criteria. Secondary end points included progression-free survival (PFS); duration of clinical benefit; overall survival (OS); and toxicity with special emphasis on DVT. Post hoc exploratory analyses included assessment of PFS in the subset of patients with or without visceral metastases; and according to expression of the androgen receptor (supplementary data S1, available at Annals of Oncology online).
Adverse events were monitored continuously throughout the study and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. The institutional review board of the Instituto Nacional de Câncer, in Brazil, approved the study, and written informed consent was obtained for each patient before study entry. A two-stage Simon design was used in order to stop the trial accrual in case of a CBR of <30%. Assuming an alpha error of 0.1 and a power of 90%, 22 patients were accrued into the first phase, proceeding to 46 patients for the final analysis. Efficacy analyses were carried out using the intention-totreat population, defined as all patients enrolled on to the study. Response rates and their 95% confidence intervals (CIs) were calculated. All reported P-values were two-sided and levels of P ≤ 0.05 were regarded as statistically significant. Both PFS and OS were calculated using Kaplan-Meier estimates.
The association of PFS with the presence of visceral metastases and the expression of the androgen receptor were evaluated as exploratory, post hoc analyses using the Cox proportional hazards model. The safety population included all patients who received any dose of study treatment.
results patients
Between January 2007 and October 2010, 48 postmenopausal women with endocrine-sensitive advanced breast cancer were enrolled, after the minimum CBR considered for the first stage was achieved and allowed continuation to the second stage of the trial.
Patients' characteristics are summarized in Table 1 . The median interval since initial diagnosis was 6.5 (range, 1-27) years. Ninety-four percent of patients previously received tamoxifen. An AI was used immediately before study entry in all cases, either as adjuvant (15%) or as therapy for metastatic disease (85%). Twenty-nine (60%) patients were on bisphosphonates upon study entry. The distribution of metastatic sites was 75%, 6%, and 19% for bone/soft tissue, visceral, and both, respectively.
efficacy
There was no complete or partial response. Nineteen patients had SD for >24 weeks, for a CBR of 39.6% (95% CI 25.2-54.9%), and the median duration of clinical benefit was 10.0 (95% CI 8.0-14.2) months (Table 2) . Median PFS for the overall patient population was 3.9 (95% CI 3.0-4.8) months (Figure 1) . At a median follow-up of 51 months, all patients had disease progression. Immediate subsequent treatment consisted of chemotherapy, hormonal treatment, and no further systemic therapy for 54%, 31%, and 15% of patients, respectively. The most common endocrine agents in sequence were exemestane (36%) and fulvestrant (36%). At the time of this analysis, 36 patients had died, and the median OS was 19.4 (95% CI 15.1-23.6) months (Figure 2 ). There was a statistically nonsignificant numeric difference in PFS according to visceral disease, with median of 3.9 and 2.8 months for patients with nonvisceral (n = 36) and visceral metastases (n = 12), respectively (P = 0.98). No difference was found for PFS according to androgen receptor expression (data not shown).
safety
All patients who received the study drugs were included in the safety evaluation. A low incidence of grade 3 side-effects was reported, and there were no grade 4 adverse events or drugrelated deaths during the study period (supplementary data S2, available at Annals of Oncology online). One (2%) patient discontinued drug study because of adverse events (DVT). Five (10.4%) patients developed lower extremity DVT, all below the knees, at a median treatment duration of 11 (range 6-15) months. Four of these patients (80%) were diagnosed with asymptomatic DVT, and no patient developed pulmonary embolism. All patients received standard anticoagulation therapy. Patients usually put on weight soon after MA started and this became more prominent with treatment continuation. Up to 45% of patients who remained on treatment at 8 months had 10% or more weight gain.
discussion
To our knowledge, this is the first prospective evaluation of MA after NSAI failure in endocrine-responsive breast cancer. MA is Our results compare favorably with other trials that evaluated single hormonal agents after breast cancer progression on a NSAI (Table 3) [1-3, 5, 11 -14] . As resistance to endocrine therapy may be related to the activation of other signaling pathways, Baselga et al. [3] evaluated the combination of exemestane with everolimus, a sirolimus derivative that inhibits mTOR, in a randomized phase III trial. The addition of everolimus improved PFS to 6.9 months, when compared with 2.8 months in the placebo arm (hazard ratio 0.43; 95% CI 0.35-0.54; P < 0.001). At the same time, the two-drug combination was associated with a higher incidence of adverse events: 19% of patients discontinued everolimus due to toxicity and 5% withdrew consent.
PFS in the current study did not vary according to the presence or absence of visceral metastases, although this analysis was underpowered. Randomized clinical trials of single endocrine agents are in agreement with our results and the presence of visceral metastases should not preclude the use of endocrine therapy [2, [15] [16] [17] .
The androgen receptor is frequently co-expressed with the ER [18] and its expression is maintained in the metastastic setting. There is evidence suggesting the AR to be prognostic as well as predictive of progestin treatment effect [19] [20] [21] . We did not show a correlation between expression of the androgen receptor and MA efficacy, although the small number of specimens available may have compromised the analysis.
The treatment benefits from MA occurred at the expense of moderate toxicity. There were no grade 4 adverse events and few patients presented with grade 3 toxicity. The most relevant untoward side-effects were weight gain and DVT. We observed only one patient with weight gain >20%, but >40% of patients had at least 10% increase in weight above baseline. Recent comparisons of MA with NSAI in advanced breast cancer showed average weight gains in the range of 9%-17% [22] [23] [24] [25] . Weight gain may become more pronounced over time, which represents an inconvenience for patients who continue treatment of longer periods.
Thromboembolic disease is another concern related to MA use. When compared with NSAI in advanced breast cancer, the incidence of combined superficial thrombophlebitis, DVT, and pulmonary embolism varied from 5% to 8% [22] [23] [24] [25] . We observed a DVT rate of 10% in this patient population. The higher rate documented in our trial may be related to the prospectively scheduled assessment through Doppler ultrasound of the lower extremities leading to the diagnosis of asymptomatic events. All patients who developed a DVT had clinical benefit on MA, with median treatment duration of 11 months. Therefore, we encourage a low threshold for the evaluation of DVT for the patients who remain on treatment.
Our study main limitation includes the unknown hormone receptor status for 17% of the patients (due to transfer from other hospitals and no remaining tissue availability) as well as receptor evaluation done at diagnosis and not at the time of disease progression. A switch in ER status, in either direction, occurs in ∼10% between primary tumor and recurrence [26] . However, clinically defined hormone sensitivity as entry criteria may have circumvented these shortcomings.
ER-positive breast cancer is a heterogeneous group of diseases with considerable variability in outcome to a range of treatments. Prior response predicts the likelihood of subsequent benefit from another endocrine agent, and this should be taken into account in the treatment decision process when assessing whether to prescribe a subsequent endocrine therapy [27] . Some patients have extended hormone-sensitive disease that benefits from multiple endocrine regimens administered sequentially. We showed that MA lacks cross-resistance and is active after acquired resistance to potent AI. However, as there are no data showing that one drug sequence is preferable to another, no definitive recommendations can be made. At the same time, despite the benefits from new pharmacologic treatments, many of them may be unavailable or limited by cost constraints. It is well recognized that treatment choices have to be made within financial boundaries and physicians may consider selecting a cheaper drug in a cost-sensitive environment [27, 28] . As such, MA, an off-patent drug, should be entertained in the treatment algorithm as a valuable option.
In summary, MA has demonstrated activity with moderate toxicity as the treatment of postmenopausal women after progression on a NSAI. Therefore, MA should be considered as an alternative in the sequence of agents for hormone-sensitive breast cancer. Despite the lack of benefit from recent reports on progesterone receptor antagonists [29] , our results support the rationale for continuing to pursue progestins as a fruitful strategy in breast cancer treatment. 
